Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.11.5557

Correlation Between Auto-antibodies to Survivin and MUC1 Variable Number Tandem Repeats in Colorectal Cancer  

Wang, Yu-Qian (National Engineering Laboratoty of AIDS Vaccine, College of Life Science, Jilin University)
Zhang, Hai-Hong (National Engineering Laboratoty of AIDS Vaccine, College of Life Science, Jilin University)
Liu, Chen-Lu (National Engineering Laboratoty of AIDS Vaccine, College of Life Science, Jilin University)
Xia, Qiu (National Engineering Laboratoty of AIDS Vaccine, College of Life Science, Jilin University)
Wu, Hui (National Engineering Laboratoty of AIDS Vaccine, College of Life Science, Jilin University)
Yu, Xiang-Hui (National Engineering Laboratoty of AIDS Vaccine, College of Life Science, Jilin University)
Kong, Wei (National Engineering Laboratoty of AIDS Vaccine, College of Life Science, Jilin University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.11, 2012 , pp. 5557-5562 More about this Journal
Abstract
Aim: The aim of this study was to investigate the frequency and correlation between auto-antibodies to survivin and MUC1 variable number tandem repeats (VNTR) in colorectal cancer (CRC), which can provide valuable information for the design of immunotherapeutic vaccines for this disease. Methods: Enzyme-linked immunosorbent assays (ELISA) were used to examine the level of auto-antibodies against survivin and MUC1 VNTR in the serum of 135 CRC patients and 95 healthy volunteers. Results: Using mean absorbance + 2 standard deviations (SD) of the healthy samples as a cut-off value, the positive rates of survivin and MUC1 VNTR auto-antibodies in CRC were 31.1% and 18.5%, respectively. Altogether, the survivin and MUC1 VNTR positive samples accounted for 36.3% of the CRC patients, and 7.4% were positive for both. Conclusion: A significant positive correlation was found between levels of specific antibodies against survivin and MUC1 VNTR in the serum of CRC patients (r = 0.3652, P < 0.0001), suggesting that vaccines against both targets would elicit immune responses more effectively.
Keywords
Survivin; MUC1 VNTR; ELISA; colorectal cancer; auto-antibody;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kameshima H, Tsuruma T, Torigoe T, et al (2011). Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci, 102, 1181-7.   DOI
2 Karanikas V, Khalil S, Kerenidi T, Gourgoulianis KI, Germenis AE (2009). Anti-survivin antibody responses in lung cancer. Cancer Lett, 282, 159-66.   DOI
3 Lladser A, Parraga M, Quevedo L, et al (2006). Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice. Immunobiology, 211, 11-27.   DOI
4 Megliorino R, Shi FD, Peng XX, et al (2005). Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev, 29, 241-8.   DOI
5 Meyerhard. JA., Mayer RJ (2005). Systemic therapy for colorectal cancer. N Engl J Med, 352, 476-87.   DOI
6 Midgley RS, Yanagisawa Y, Kerr DJ (2009). Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol, 6, 108-20.   DOI
7 Nakamura H, Hinoda Y, Nakagawa N, et al. (1998). Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol, 33, 354-61.   DOI
8 Penland S K, Goldberg RM (2004). Current strategies in previously untreated advanced colorectal cancer. Oncology (Williston Park), 18, 715-22, 727; discussion 727-9.
9 Rohayem J, Diestelkoetter P, Weigle B, et al (2000). Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res, 60, 1815-7.
10 Silk AW, Schoen RE, Potter DM, Finn OJ (2009). Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol Immunol, 47, 52-6.   DOI
11 Speetjens FM, Zeestraten EC, Kuppen PJ, Melief CJ, van der Burg SH (2011). Colorectal cancer vaccines in clinical trials. Expert Rev Vaccines, 10, 899-921.   DOI
12 Tang CK, Katsara M, Apostolopoulos V (2008). Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines, 7, 963-75.   DOI
13 Tang Y, Wang L, Zhang P, et al (2010). Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Clin Vaccine Immunol, 17, 1903-8.   DOI
14 Toubi E, Shoenfeld Y (2007). Protective autoimmunity in cancer (review). Oncol Rep, 17, 245-51.
15 Wan DS (2009). Epidemiologic trend of and strategies for colorectal cancer. Ai Zheng, 28, 897-902.
16 Yagihashi A, Ohmura T, Asanuma K, et al (2005). Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin Chim Acta, 362, 125-30.   DOI
17 Yip KW, Shi W, Pintilie M, et al (2006). Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res, 12, 5726-32.   DOI
18 Yuan S, Shi C, Ling R, et al (2010). Immunization with two recombinant Bacillus Calmette-Guerin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice. J Cancer Res Clin Oncol, 136, 1359-67.   DOI
19 Zhang JY, Casiano CA, Peng XX, et al (2003). Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev, 12, 136-43.
20 Zhang HH, Zhang SZ, Zhao DH, et al (2008). Construction and expression of human survivin and preparation of its polyclonal antibody. Chem Res Chinese Universities, 24, 767-70.
21 Chakravarti A, Noll E, Black PM, et al (2002). Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol, 20, 1063-8.   DOI   ScienceOn
22 Al-Joudi FS, Iskandar ZA (2006). Autoantibodies to survivin in the sera of patients with infiltrating ductal carcinoma of the breast. Med J Malaysia, 61, 302-6.
23 Ambrosini G, Adida C, Altieri DC (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med, 3, 917-21.   DOI   ScienceOn
24 Apostolopoulos V, McKenzie IF (1994). Cellular mucins: targets for immunotherapy. Crit Rev Immunol, 14, 293-309.   DOI
25 Chen JS, Chen KT, Fan WC, et al (2010). Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer. Clin Chem Lab Med, 48, 719-25.
26 Chung MH, Gupta RK, Hsueh E, et al (2003). Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J Clin Oncol, 21, 313-9.   DOI
27 Coronella-Wood JA, Hersh EM (2003). Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother, 52, 715-38.   DOI
28 Dermime S, Armstrong A, Hawkins RE, Stern PL (2002). Cancer vaccines and immunotherapy. Br Med Bull, 62, 149-62.   DOI
29 Finn OJ, Jerome KR, Henderson RA, et al (1995). MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev, 145, 61-89.   DOI
30 DiFronzo LA, Gupta RK, Essner R, et al (2002). Enhanced humoral immune response correlates with improved diseasefree and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol, 20, 3242-8.   DOI
31 Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J (1988). A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem, 263, 12820-3.
32 Green MC, Murray JL, Hortobagyi GN (2000). Monoclonal antibody therapy for solid tumors. Cancer Treat Rev, 26, 269-86.   DOI
33 Hirasawa Y, Kohno N, Yokoyama A, et al (2000). Natural autoantibody to MUC1 is a prognostic indicator for nonsmall cell lung cancer. Am J Respir Crit Care Med, 161, 589-94.   DOI
34 Hobday TJ (2005). An overview of approaches to adjuvant therapy for colorectal cancer in the United States. Clin Colorectal Cancer, 5, S11-8.   DOI
35 Howat JM, Moore M, Hilton AM, Kimber I (1979). Inhibition of antibody-dependent cellular cytotoxicity by artificial immune complexes and pathological sera. Immunology, 37, 467-75.
36 Hull SR, Bright A, Carraway KL, et al (1989). Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun, 1, 261-7.
37 Ishizaki H, Manuel ER, Song GY, et al (2011). Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother, 60, 99-109.   DOI